VEGFA and neoplasm: In line with this situation, preclinical studies have shown that the pre-administration of anti-VEGF reduces the intratumoral accumulation of therapeutic antibodies [72–74, 76] and control IgG [76], along with the reductions of tumor blood flow and vessel density.